Main description:

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies.

Contents:

A Personal Essay: My Experiences in the Pharmaceutical Industry
Adventures in Medicinal Chemistry - A Career in Drug Discovery
Natural and Synthetic Neuroactive Steroid (NAS) Modulators of GABAA and NMDA Receptors
Development of LRRK2 Kinase Inhibitors for Parkinson's Disease
Stimulating Neurotrophin Receptors in the Treatment of Neurodegenerative Disorders
Small Molecule Modulators of GPR40 (FFA1)
Recent Advances in the Development of P2Y12 Receptor Antagonists as Antiplatelet Agents
Current Approaches to the Treatment of Atrial Fibrillation
Advances in the Discovery of Small Molecule IRAK4 Inhibitors
H4 Receptor Antagonists and Their Potential Therapeutic Applications
Urate Crystal Deposition Disease and Gout - New Therapies for an Old Problem
p53 - MDM2 and MDMX Antagonists
Modulators of Atypical Protein Kinase C as Anticancer Agents
Advancement of Cell Wall Inhibitors in Mycobacterium Tuberculosis
Nucleosides and Nucleotides for the Treatment of Viral Diseases
Advances in Inhibitors of Penicillin Binding Proteins and ss-lactamases as Antibacterial Agents
Tumor Microenvironment as Target in Cancer Therapy
Novel Screening Paradigms for the Identification of Allosteric Modulators and /or Biased Ligands for Challenging G-Protein-Coupled Receptors (GPCRs)
Mer Tyrosine Kinase Receptor: Therapeutic Opportunities in Oncology, Virology and Cardiovascular Indications
Disease Modifying Agents for the Treatment of Cystic Fibrosis
Advancements in Stapled Peptide Drug Discovery and Development
Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development
Case History: ForxigaTM (Dapagliflozin), a Potent Selective SGLT2 Inhibitor for Treatment of Diabetes
Case History: Kalydeco (R) (VX-770, Ivacaftor), a CFTR Potentiator for the Treatment of Patients with Cystic Fibrosis and the G551D-CFTR Mutation
Case History: XeljanzTM (Tofacitinib Citrate), A First-In-Class Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis
New Chemical Entities Entering Phase III Trials in 2013
To Market, To Market - 2013